QA
ACRS icon

Quattro Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Quattro Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-372
Closed -$1.12K – 62
2025
Q4 		$1.12K Buy
+372
New +$940 ﹤0.01% 429

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Quattro Advisors's ACRS Position: Q1 2026 in Review

Quattro Advisors sold out of Aclaris Therapeutics (ACRS) in Q1 2026, closing a stake of 372 shares — an estimated $1.12K sold.

Quattro Advisors first reported a position in ACRS in Q4 2025 and held it in 1 quarter. The position peaked at $1.12K in Q4 2025. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Quattro Advisors reported no remaining Aclaris Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Quattro Advisors sold 372 Aclaris Therapeutics shares in Q1 2026, an estimated $1.12K.
  • Quattro Advisors first reported a position in Aclaris Therapeutics in Q4 2025 and held it in 1 quarter.
  • Quattro Advisors's Aclaris Therapeutics position peaked at $1.12K in Q4 2025.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Quattro Advisors's 13F filing for Q1 2026, filed 15 May 2026.